Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk. Issue 164 (April 2018)

• Record Type: Journal Article
• Authors: Liebman, Howard A.
• Is Part Of: Thrombosis research. Issue 164(2018)Supplement 1
• Page Start: S19
• Page End: S22
• Publication Date: 2018-04
• Subjects: Venous thromboembolism -- Cancer prognosis -- VTE-risk biomarkers; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2018.01.040
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Venous thromboembolism (VTE) is a well-documented complication of cancer and its treatment. While VTE contributes significant morbidity and some thrombotic mortality to cancer patients, a growing body of clinical and experimental data supports the finding that VTE is an important prognostic marker for cancer progression and mortality. This would suggest that hemostatic activation is an expression of an aggressive tumor phenotype. A number of clinical and laboratory biomarkers have been shown to be predictive of an increased risk of cancer-associated VTE. In addition, it is now becoming apparent that these same biomarkers are also predictive of cancer mortality. The application of this information to reduce cancer-associated VTE and improve cancer survival await the results of ongoing prophylaxis antithrombotic studies. Highlights: Venous thromboembolism (VTE) is a complication of cancer and its occurrence is tumor type, stage and treatment related. Certain clinical and laboratory biomarkers have been shown to be predictive of an increased risk of cancer-associated VTE. The development of a VTE during the course of cancer treatment is predictive of a worse cancer-related survival. VTE predictive clinical and laboratory biomarkers are also predictive of a worse cancer-related survival.